MedTrace Logo

Clinical Study to Evaluate the Safety and Efficacy BMMNC in Cerebellar Ataxia

NCT01958177 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2014-09-17

No results posted yet for this study

Summary

Cerebellar ataxia is a complex motor disturbance, which, can occur as a result of many diseases and presents with symptoms of an inability to coordinate balance, gait, extremity and eye movements. Lesions to the cerebellum can cause dyssynergia, dysmetria, dysdiadochokinesia, dysarthria and ataxia of stance and gait. Deficits are observed with movements on the same side of the body as the lesion (ipsilaterally).

Conditions

  • Cerebellar Ataxia

Interventions

BIOLOGICAL

Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)

Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell BMMNCs)

Sponsors & Collaborators

  • Chaitanya Hospital, Pune

    lead OTHER

Principal Investigators

  • ANANT E BAGUL, MS ORTHO · Chaitanya Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2016-12-31
Completion
2016-12-31

Countries

  • India

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01958177 on ClinicalTrials.gov